Straumann Holding AGXSWX:STMN +1.50%100 EV-to-EBITDA is 26.59 as of Jul. 11, 2026, which is 14% below its 10-year median of 31.08. GuruFocus rates XSWX:STMN with a GF Score™ of 100/100 and a GF Value™ of CHF137.43 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 74.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Straumann Holding AG's enterprise value is CHF16,708 Mil.
Straumann Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF628 Mil. Therefore, Straumann Holding AG's EV-to-EBITDA for today is 26.59.
The historical rank and industry rank for Straumann Holding AG's EV-to-EBITDA or its related term are showing as below:
XSWX:STMN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 19.15 Med: 31.08 Max: 142.97
Current: 26.59
During the past 13 years, the highest EV-to-EBITDA of Straumann Holding AG was 142.97. The lowest was 19.15. And the median was 31.08.
XSWX:STMN's EV-to-EBITDA is ranked worse than 74.56% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.2
vs XSWX:STMN: 26.59
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Straumann Holding AG (XSWX:STMN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Straumann Holding AG's PE Ratio (TTM) for today is calculated as:
Straumann Holding AG's share price for today is CHF105.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Straumann Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF2.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Straumann Holding AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:STMN vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's EV-to-EBITDA falls into.
Straumann Holding AG's current Enterprise Value is CHF16,708 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Straumann Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF628 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG (XSWX:STMN) has a EV-to-EBITDA of 26.59 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Straumann Holding AG. This is 14% below median its historical median of 31.08. Over the past decade, Straumann Holding AG's EV-to-EBITDA has ranged from 19.15 to 142.97. According to the industry distribution chart, Straumann Holding AG ranks #381 out of 511 companies in the Medical Devices & Instruments industry, placing it in the top 74.6%.
Is Straumann Holding AG's EV-to-EBITDA too high?
Straumann Holding AG's current EV-to-EBITDA of 26.59 is 14% below median its 10-year median of 31.08. Over the past 10 years, this metric has ranged from a low of 19.15 to a high of 142.97. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.20. Straumann Holding AG's value of 26.59 is 87.3% above this industry median. Based on the distribution chart, Straumann Holding AG ranks #381 out of 511 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Straumann Holding AG has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #381 out of 511 companies for EV-to-EBITDA. This places Straumann Holding AG in the lower half of its industry. The industry median EV-to-EBITDA is 14.20. Straumann Holding AG's value of 26.59 is 87.3% above this benchmark. Historically, Straumann Holding AG's own EV-to-EBITDA has ranged from 19.15 to 142.97 over the past decade. While the company's 10-year median is 31.08 vs. the industry median of 14.20, Straumann Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.20, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current EV-to-EBITDA of 26.59 is 87.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Straumann Holding AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current EV-to-EBITDA is 26.59, which is 14% below median its own 10-year median of 31.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF137.43, compared to a current price of CHF105.20 — trading 23.5% below its estimated fair value. The current EV-to-EBITDA is 26.59, which is 14% below median its 10-year median of 31.08 and 87.3% above the Medical Devices & Instruments industry median of 14.20. Straumann Holding AG's overall GF Score™ is 100/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current EV-to-EBITDA is 26.59 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF105.20 is trading 23.5% below its estimated GF Value™ of CHF137.43.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
EV-to-EBITDA: 26.59 (14% below median its 10-year median of 31.08)
GF Value™: CHF137.43 vs. price of CHF105.20 (23.5% below fair value)
Industry Position: 87.3% above the Medical Devices & Instruments median (#381 of 511)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
100GF Score
Get the complete analysis for XSWX:STMN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
